COTA and Sanofi collaborate to accelerate multiple myeloma trials through real-world data insights

COTA will partner with Sanofi to expedite cancer trials, focusing on multiple myeloma treatment questions. Their collaboration aims to enhance trial design, improve patient outcomes, and expedite breakthrough treatments using real-world data (RWD) and AI technologies.

The proposed joint initiative aims to address a series of relevant questions related to the treatment of multiple myeloma. Through this collaboration, the organizations aim to deepen the understanding of the evolving treatment landscape for this disease.

The anticipated outcomes of this partnership will have the potential to shape the design of future clinical trials for oncology, with a focus on multiple myeloma treatments. By addressing key questions and gaps in the current understanding, the project can help to ensure that future trials are more targeted and effective. It is also expected that the insights gained from this initiative may contribute to a better understanding of both future and ongoing clinical studies in the context of the current standard of care for oncology patients, including those with multiple myeloma.

COTA, which was founded by oncologists and provides RWD and analytics in this area, will collaborate with Sanofi, a global pharmaceutical company, to leverage RWD and AI in expediting cancer trials, with a specific focus on multiple myeloma. The aim of this partnership is to yield invaluable insights into clinical outcomes that could ultimately benefit cancer patients.

When paired with Sanofi’s resources and expertise, COTA’s oncology analytics and RWD will give crucial insights into efficient cancer treatment routes along with useful information on key patient populations.

Dr CK Wang, an oncologist and COTA’s Chief Medical Officer, highlighted the potential of this collaboration, stating,

“Our collaboration with Sanofi has the potential to enable more patients and their families to benefit from breakthrough treatments in an expedited time frame. We are providing high-quality RWD enabled by new AI-based tools to accelerate pharmaceutical research and improve patient care.”